Sertraline — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Anxiety

• Buspirone
• Escitalopram

Also listed for Anxiety Disorder

• Alprazolam
• Duloxetine
• Lorazepam
• Paroxetine
• Venlafaxine

Also listed for Depression

• Citalopram

Other medications in Mental Health

• Suvorexant
• Temazepam
• Thioridazine
• Thiothixene
• Tranylcypromine
• Trazodone
• Triazolam
• Trifluoperazine

What Sertraline is approved for (FDA label)

Sertraline hydrochloride tablets are indicated for the treatment of the following [ See Clinical Studies ( 14 ) ]: • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD) Sertraline hydrochloride tablets are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of ( 1 ): • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD)

Source: Read the full FDA label on DailyMed. Label effective date: August 20, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Sertraline (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ See Warnings and Precautions ( 5.1 ) ]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients ( 5.1 ) • Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sertraline (FDA label)

25 mg tablets: light green, film coated, elliptical shaped, scored on one side of the tablet and debossed with "757" on the other side. 50 mg tablets: light blue, film coated, elliptical shaped, scored on one side of tablet and debossed with "758" on the other side. 100 mg tablets: light yellow, film coated, elliptical shaped, scored on one side of tablet and debossed with "759" on the other side. • Tablets: 25 mg, 50 mg and 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sertraline (FDA label)

The following adverse reactions are described in more detail in other sections of the prescribing information: • Hypersensitivity reactions to sertraline [See Contraindications ( 4 )] • QTc prolongation and ventricular arrhythmias when taken with pimozide [See Contraindications ( 4 ), Clinical Pharmacology ( 12.2 )] • Suicidal thoughts and behaviors [See Warnings and Precautions ( 5.1 )] • Serotonin syndrome [See Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 )] • Increased risk of bleeding [See Warnings and Precautions ( 5.3 )] • Activation of mania/hypomania [See Warnings and Precautions ( 5.4) ] • Discontinuation syndrome [See Warnings and Precautions ( 5.5 )] • Seizures [See Warnings and Precautions ( 5.6 )] • Angle-closure glaucoma [See Warnings and Precautions ( 5.7 )] • Hyponatremia [See Warnings and Precautions ( 5.8 )] • Sexual Dysfunction [See Warnings and Precautions ( 5.11 )] Most common adverse reactions (>5% and twice placebo) in pooled placebo-controlled MDD, OCD, PD, PTSD, SAD and PMDD clinical trials were nausea, diarrhea/loose stool, tremor, dyspepsia, decreased appetite, hyperhidrosis, ejaculation failure, and decreased libido. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sertraline (FDA label)

Sertraline hydrochloride tablets are contraindicated in patients: • Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [ See Warnings and Precautions ( 5.2 ), Drug Interactions ( 7.1 ) ]. • Taking pimozide [ See Drug Interactions ( 7.1 ) ]. • With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [ See Adverse Reactions ( 6.1 , 6.2 ) ]. • Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs ( 4 , 7.1 ) • Concomitant use of pimozide ( 4 , 7.1 ) • Known hypersensitivity to sertraline or excipients ( 4 , 5.4 )

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Sertraline (FDA label)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone.

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Sertraline (FDA label)

• Protein-bound drugs: Monitor for adverse reactions and reduce dosage of sertraline hydrochloride or other protein-bound drugs (e.g., warfarin) as warranted. ( 7.1 , 12.3 ) • CYP2D6 substrates: Reduce dosage of drugs metabolized by CYP2D6. ( 7.1 , 12.3 ) 7.1 Clinically Significant Drug Interactions Table 5 includes clinically significant drug interactions with sertraline hydrochloride [See Clinical Pharmacology ( 12.3) ]. Table 5. Clinically Significant Drug Interactions with Sertraline Hydrochloride Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: The concomitant use of SSRIs including sertraline hydrochloride and MAOIs increases the risk of serotonin syndrome.

Source: FDA prescribing information (DailyMed). Set ID: 957ba196-0b9b-4cda-bd15-28357ced8d2f. Label effective date: August 20, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.